Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer Frontiers in Oncology 2024;14
Date
01/01/2024DOI
10.3389/fonc.2024.1291090Scopus ID
2-s2.0-85186485797 (requires institutional sign-in at Scopus site)Author List
Uyar D, Michener CM, Bishop E, Hopp E, Simpson P, Zhang L, Rader JS, Rose PG, Mahdi HS, Debernardo R, Christian Q, Bradley WAuthors
William H. Bradley MD Professor in the Obstetrics and Gynecology department at Medical College of WisconsinElizabeth E. Hopp MD Assistant Professor in the Obstetrics and Gynecology department at Medical College of Wisconsin
Janet Sue Rader MD Chair, Professor in the Obstetrics and Gynecology department at Medical College of Wisconsin
Pippa M. Simpson PhD Adjunct Professor in the Pediatrics department at Medical College of Wisconsin
Denise S. Uyar MD Professor in the Obstetrics and Gynecology department at Medical College of Wisconsin